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Fatal ischemic acute pancreatitis complicating trans-catheter
arterial embolization of small hepatocellular carcinoma:
Do the risks outweigh the beneﬁts?q
Luigi Addario1, Giovan Giuseppe Di Costanzo1, Giovanni Tritto1,*, Enrico Cavaglia`2,
Basilio Angrisani3, Antonio Ascione1
1Hepatology Unit, Department of Gastroenterology, Cardarelli Hospital, Napoli, Italy
2Interventional Radiology Unit, Department of Radiology, Cardarelli Hospital, Napoli, Italy
3Institute of Pathology, University ‘‘Federico II ”, Napoli, ItalyHepatocellular carcinoma (HCC) is an accepted indication for liver transplantation (LT). Pre-LT adjuvant ablation
treatments to prevent tumour progression and drop out from the waiting list have been increasingly adopted at most trans-
plant centers. Trans-catheter arterial chemo-embolization (TACE) is frequently used, but the procedure can be diﬃcult
and severe complications may arise. Among them, acute ischemic pancreatitis occasionally occurs and may clinically
mimic a post-embolization syndrome. Fatal outcomes of this complication have been reported exceptionally but never
in patients awaiting LT. The present case raises concern about the widespread application of TACE and highlights the
need for a critical evaluation of the risks and beneﬁts to patients with monofocal small HCC who are scheduled for
LT. Superselective embolization of the tumour-feeding artery and systematic monitoring of serum pancreatic enzymes
after this radiological procedure are recommended.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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ing HCC prior to transplant is intended to bridge the
waiting time before an organ becomes available. How-
ever, the choice of treatment is still controversial. None
of the available therapies has been shown to provide
unequivocal beneﬁt in terms of improved survival [1].
Moreover, there is no ﬁrm evidence as to the optimal
ﬁrst-line treatment for small single HCC in patients
awaiting LT. Trans-catheter arterial chemo-emboliza-
tion (TACE) is often employed because it reduces
tumour burden, delays tumour progression and leads
to an excellent outcome [2,3]. TACE can lead to several
possible complications, although resulting fatality is
very uncommon [4–6]. We describe a rare case of fatal
ischemic acute pancreatitis (AP) following TACE in a
patient with HCC awaiting LT.Published by Elsevier B.V. All rights reserved.
Fig. 1. Selective arteriography showing the tumour nodule before (a) and
after (b) chemo-embolization.
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In July 2004, a 62-year-old Caucasian male aﬀected
with HCC complicating hepatitis C virus-related cirrho-
sis was referred to the Liver Unit of the Cardarelli Hos-
pital (Napoli, Italy) for pre-transplant evaluation. His
liver disease could be traced back to 1982, while diagno-
sis of HCV-related active chronic hepatitis was con-
ﬁrmed by means of a liver biopsy in 1991. The patient
did not respond to two 12-month courses of alpha-inter-
feron. In 2002, upper gastrointestinal endoscopy
revealed small varices. In May 2004, during routine con-
trols, a 22-mm single hypoechoic lesion in segment VIII
was detected by ultrasonography (US) along with
increased values of alpha-fetoprotein (100 ng/ml; nor-
mal range <10).
On admission, the patient was asymptomatic; clinical
examination revealed mildly enlarged liver and spleen
but no signs of liver decompensation. The Child-Tur-
cotte-Pugh grade was B (score 7), MELD score was
11. Laboratory ﬁndings were as follows: haemoglobin
13.1 g/dl, hematocrit 37%, white blood cell count
(WBC) 2700/mm3, platelet count 61.000/mm3, ALT
45 U/l (normal range 0–40), AST 61 U/l (normal range
0–40), alkaline phosphatase 261 UI/l (normal range
40–130), cGT 177 UI/l (normal range 10–71), total bili-
rubin 1.3 mg/dl, direct bilirubin 0.5 mg/dl; albumin
2.9 g/dl, cholinesterase 2600 UI/l (normal >3000),
gamma-globulin 1.6 g/dl, prothrombin time-INR 1.32.
Viral markers were: HBsAg, HBsAb, HbcAb negative;
anti-HCV + ve, HCV-RNA + ve and HCV-genotype
1b; AFP 109 ng/ml; blood group O Rh+.
Helical computed tomography (CT) and magnetic
resonance imaging conﬁrmed the presence of a 22 mm
nodule in liver segment VIII with an early enhancement
on the arterial phase and complete ‘‘washout”of the
lesion on the portal venous phase. According to the
EASL criteria [7], diagnosis of HCC was made and the
patient was included in the transplant list and scheduled
for TACE.
TACE was performed by an expert interventional
radiologist and involved selective embolization of the
hepatic artery branches feeding the tumour with a mix-
ture of lipiodol (10 mL) and a cytotoxic agent (farmoru-
bicin 50 mg/25 ml). Subsequent embolization of the
feeding arteries was supplemented by using super absor-
bent polyvinyl alcohol (PVA) particles (Contour
Emboli, Interventional Therapeutics Corp, Fremont,
CA) to enhance the ischemic and chemotherapeutic
eﬀects (Fig. 1a and b).
On the ﬁrst post-procedure day, the patient complained
of poor appetite, nausea, fever, fatigue and abdominal
pain. Laboratory results showed increased AST (260 U/
l), ALT (200 U/l), alpha-amylase 439 UI/l (normal range
5–220), lipase 98 UI/l (normal range <60), WBC 13,000/
mm3 (with 87% neutrophils), total bilirubin 3.1 mg/dl.Abdominal US showed no lesions in the pancreas and
no ascites. The patient was discharged on day 4 with nor-
malised pancreatic enzymes. Oral ﬂuoro-quinolones were
prescribed for 7 days at home.
Three weeks later the patient was re-admitted to our
Unit for fever and abdominal pain.US revealedmild asci-
tes, patent portal vein, enlarged spleen. Emergency CT
scan showed the signs of eﬀectiveTACE (hyperdense nod-
ule in segment VIII with no focal enhancement in the dif-
ferent phases) (Fig. 2A), mild ischemia of the inferior
spleen lobe and a 6-cm biloculated pseudocyst in the head
of the pancreas (Fig. 2B). Despite antibiotic therapy with
high-dose i.v. imipenem and metronidazole the patient
gradually worsened. Bacterial peritonitis (positive for
Pseudomonas aeruginosa) developed, followed by septic
syndrome and multiorgan failure. The patient eventually
died two months after TACE.3. Discussion
Treatment of HCC in patients awaiting LT has
become a widespread practice, aimed at improving
Fig. 2. CT scan performed 3 weeks after TACE. (A) Hyperdense treated
HCC nodule in segment VIII with no focal enhancement in diﬀerent
phases. (B) Acute pancreatitis with an about 6 cm biloculated pseudocyst
(arrowheads) in the head of the pancreas.
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advanced HCC [8], and preventing drop out from LT
candidacy. Chemo-embolization, radiofrequency abla-
tion and percutaneous ethanol injection all have well-
documented antineoplastic eﬃcacy; however, there is
no ﬁrm evidence that HCC treatment with any of these
modalities is able to achieve any of the three aforemen-
tioned goals.
TACE is increasingly popular in the treatment of
HCC [9–11] and can play an important role as a bridge
to transplantation. Although eﬀective, TACE can lead
to infrequent albeit signiﬁcant complications and rare
mortality. Severe complications range from 2 to 7%
and 30-day mortality has been reported in 1–2% [12–
14]. The most frequent adverse events of this procedure
are post-embolization syndrome and deterioration of
liver function, occurring in 2.5–15% of patients [15–17].
Acute pancreatitis can occur following TACE, with
an incidence ranging from 1.7% (acute clinically overt
pancreatitis) to 40% (biological pancreatitis). Lethal
outcome from this complication is generally low (1–
2%) but can be as high as 30–50% when sepsis and mul-
tiorgan failure develop [18,19].
Ischemic damage to the pancreas is usually due to unin-
tentional embolization of the vessels supplying the organbecause of regurgitation of embolic materials [20]. In the
above-described case AP developed probably because
PVA particles regurgitated into the pancreaticoduodenal
artery and occluded a high peripheral portion of the pan-
creatic vascular bed, leading to ischemia of the pancreas.
Extrahepatic uptake of chemo-embolization material in
other organs is relatively common but usually does not
cause problems, presumably because the dose deposited
outside the liver is small [6]. Consequently, during TACE
the catheter tip should be placed as close to the distal
branches of the hepatic artery as possible in order to pre-
vent ischemic complications, and injection of embolic
materials should be done carefully, to avoid regurgita-
tion. In the present case, regurgitation of embolic materi-
als was not noticed during the procedure, and
arteriography after TACE showed no occlusion of the
gastroduodenal artery and its branches. Nevertheless, it
is reasonable to hypothesize that a non-recorded reﬂux
of embolic material occluded the collateral blood vessels
to the pancreas due to the increased hepatic arterial resis-
tance related to cirrhosis [20].
Symptoms of AP, such as abdominal pain, fever, nau-
sea, vomiting, are frequently observed after TACE, irre-
spective of whether acute pancreatitis has developed.
Thus, the onset of AP should be kept in mind even when
it is thought that TACE has been performed safely, and
measurement of pancreatic enzymes is recommended for
the early detection of this complication. In the present
case, the fatal ischemic pancreatitis developed late in
the post-TACE course. The early mild elevation of pan-
creatic enzymes following TACE was rapidly and spon-
taneously resolved within 48 h, encouraging the
discharge of the patient. Moreover, the well-known
symptoms of post-embolization syndrome occur in most
patients and can persist for up to 10 days [21]. Since AP
can clinically mimic a post-embolization syndrome, a
more careful monitoring of serum pancreatic enzymes
would be advisable in cases of abdominal pain following
TACE.
Although a case of fatal post-TACE pancreatitis was
recently reported in a patient with multifocal HCC unﬁt
for transplantation [22], to our knowledge this is the ﬁrst
case of a patient who died of post-TACE pancreatitis
while on the waiting list. Despite general acceptance
by the transplant community, few objective data have
demonstrated pre-transplant TACE eﬃcacy or
improved post transplant outcomes in HCC patients.
TACE procedures are technically demanding and
should be restricted to appropriate candidates. It was
proposed that the best candidates for LT would be
patients with solitary HCC 65 cm or up to three nod-
ules 63 cm [8]. However, there is an urgent need to iden-
tify strong predictors of progression while patients are
on the waiting list. Ongoing genomic and proteomic
studies will characterize HCC more accurately, so that,
in the future, HCC patients may be classiﬁed and treated
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to the rough evaluation of tumour burden and conven-
tional measures of liver function [23].
The negative outcome recorded herein raises the issue
of the appropriateness of pre-LT adjuvant treatments in
patients with compensated liver disease and small single
nodule HCC. Potentially fatal complications of TACE,
such as the one described, should be held in due consid-
eration in the decision process and a clinically sound
balance of risks and beneﬁts in selected cases should
be assessed.References
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